Myriad Genetics, Inc. (NASDAQ:MYGN) recovered 63.3% of its value since hitting low of $15.15. The recent move of -2.37% drop pushed the stock to close at $24.74 when trading ended on Jul. 14, 2017. At recent session, the prices were hovering between $24.65 and $25.46. This company shares are -16.73% up from its target price of $20.6 and the current market capitalization stands at $1.71B. The recent change has given its price a 6.93% lead over SMA 50 and -23.97% deficit over its 52-week high. The stock witnessed 7.38% gains, 36.31% gains and 51.13% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MYGN’s volatility during a week at 2.8% and during a month it has been found around 3.36%.

Myriad Genetics, Inc. 13F Filings

At the end of recent reporting period, 135 institutional holders increased their position in Myriad Genetics, Inc. (NASDAQ:MYGN) by some 15,223,671 shares, 89 decreased positions by 11,582,638 and 36 held positions by 57,969,094. That puts total institutional holdings at 84,775,403 shares, according to SEC filings. The stock grabbed 40 new institutional investments totaling 1,423,218 shares while 31 institutional investors sold out their entire positions totaling 4,609,520 shares.

Myriad Genetics, Inc. (NASDAQ:MYGN) Insider Trades

Multiple company employees have indulged in significant insider trading. Myriad Genetics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director HENDERSON JOHN T has acquired 6,000 shares of Myriad Genetics, Inc. (MYGN) in trading session dated Feb. 23, 2017. These shares are worth $111,960 and were traded at $18.66 each. The SEC filing shows that HENDERSON JOHN T performed a sale of 30,000 shares. The Director disposed these shares by way of transaction on Sep. 12, 2016. The company’s shares were given away at $20.49 per share worth to an income of some $614,700 on account of HENDERSON JOHN T.

President & C.E.O., Capone Mark Christopher, purchased 10,000 common shares of Myriad Genetics, Inc. (MYGN) in the open market. In a transaction dated Aug. 19, 2016, the shares were bought at an average price of $21.24, giving away a sum of $212,400. After this purchase, 146,026 common shares of MYGN are directly owned by the insider, with total stake valued at $3,612,683.

In the transaction dated Aug. 12, 2016, the great number of shares acquired came courtesy the President Myriad RBM, Inc.; McDade Ralph L added a total of 1,000 shares at an average price of $21.49, amounting to approximately $21,490. The insider now directly owns 56,720 shares worth $1,403,253.

Myriad Genetics, Inc. (MYGN) Analyst Guide

Several analysts have released their opinion on Myriad Genetics, Inc. (NASDAQ:MYGN), with 2 analysts believing it is a strong buy. Whereas 7 of them predict the stock is a hold. Also, there are 0 buy, 1 sell and 4 strong sell ratings, collectively assigning a 3.31 average brokerage recommendation.

Previous articleAnalyst Views On Top Movers In Recent Trade: Centennial Resource Development, Inc. (CDEV), Itau Unibanco Holding S.A. (ITUB)
Next articleXilinx, Inc. (XLNX) loses confidence of 73 hedge fund managers